Figure S3 from Population-based Screening for <i>BRAF</i><sup>V600E</sup> in Metastatic Colorectal Cancer Reveals Increased Prevalence and Poor Prognosis

Kaplan-Meier estimation of overall survival of mCRC patients with BRAFV600E mutations detected by (A) IHC (BRAFIHC) and (B) NGS (BRAFNGS) demonstrates no survival difference between those with dMMR versus pMMR for BRAFIHC and BRAFNGS within individual groups.